Trial Profile

Rituximab on Adult-onset frequenTly rElApsing or steroid dependent nephrotic syndrome study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary)
Indications Nephrotic syndrome
Focus Therapeutic Use
Acronyms A-TEAM

Most Recent Events

19 Jun 2026 According to Zenyaku Kogyo media release, company announced that Zenyaku, obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW), for an additional dosage and administration of an anti-CD20 monoclonal antibody Rituxan intravenous infusion 100 mg and 500 mg,which is co-promoted by both companies, for adult-onset frequently relapsing or steroid-dependent nephrotic syndrome.
29 Jun 2022 Status changed from recruiting to active, no longer recruiting.
04 Feb 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com